Opinion|Videos|September 10, 2024
HMA Persistence and Effectiveness in Higher Risk MDS
Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What insights do you have on the persistence and effectiveness of hypomethylating agents in patients with higher-risk myelodysplastic syndromes, and how do these data inform treatment decisions?
- Please include a discussion of 65th American Society of Hematology Annual Meeting and Exposition abstract 548 by Zeidan et al.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
National HIV Testing Day Highlights Expanding PrEP, PEP Access, Persistent Barriers
3
Treatment Burden, End-of-Life Symptom Gaps in Multiple Myeloma
4
Health Equity & Access Weekly Roundup: June 26, 2026
5